NCT05688787

Efficacy of Perineural Injection Therapy in Primary Fibromyalgia

Status unknown NA Last updated 18 January 2023

What this trial tests

NA trial testing Perineural Injection in Fibromyalgia, Primary in 60 participants. Status unknown.

Timeline

1 April 2023

Primary endpoint
30 June 2023

31 July 2023

Quick facts

Lead sponsor	Cairo University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 April 2023
Primary completion	30 June 2023
Estimated completion	31 July 2023
Sites	1 location across Egypt

Drugs / interventions tested

• Perineural Injection — full drug profile →

Conditions studied

• Fibromyalgia, Primary — all drugs for Fibromyalgia, Primary →

Sponsor

Cairo University

Who can join

18 and older, any sex, with Fibromyalgia, Primary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of fibromyalgia Treatment is to relieve the pain and improve quality of life and physical function which need a

Final Version: April 2019Research Template 3 multifaceted treatment approach involving non pharmacological pain management and medicine

Lyftgot perineural injection therapy \"lyftgot PIT\" previously known as neural prolotherapy , is a method of injection treatment designed and developed by DR Lyftgot from new Zealand to treat the neurogenic inflammation and the neuropathic pain caused by the sensocrine small nerve fiber .PIT is based on the injection of small amount of dextrose 5%in a neutral PH sterile water solution in the subcutaneous tissue around the sick nerve to correct the neuroglycopenia and to inhibit the neurogenic inflammation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.